<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "zoledronic acid inj VIAL">
<dose><value>4</value>
<value>5</value>
</dose>
<route><value>IV</value>
</route>
<strength><value>0.8 mg/mL</value>
</strength>
<frequency><value>ONCE</value>
</frequency>
<instruction></instruction>
<volume><value>5 mL</value>
</volume>
<units><value>mg</value>
</units>
<Population><value>ADULT</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>Hypercalcemia, Bone metastases and osteolytic lesions (CrCl greater than 60mL/minute.). The benefits of bisphosphonate drugs in preventing fractures associated with osteoporosis outweigh the risk of an atypical femur fracture (Health Canada; December 19, 2011)</value>
<value>Osteoporosis in postmenopausal women, glucocorticoid-induced in men. Administered annually. The benefits of bisphosphonate drugs in preventing fractures associated with osteoporosis outweigh the risk of an atypical femur fracture (Health Canada; December 19, 2011)</value>
<value>Prevention of postmenopausal osteoporosis, Paget&amp;apos;s disease. The benefits of bisphosphonate drugs in preventing fractures associated with osteoporosis outweigh the risk of an atypical femur fracture (Health Canada; December 19, 2011)</value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3606</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>Formulary with Restrictions.</value>
</AHSFormularyStatus>
<AHFSName><value>Bone Resorption Inhibitors</value>
</AHFSName>
<HighAlert></HighAlert>
</drug>